Advertisement


Peter Riedell, MD, on DLBCL: Expert Commentary on Data From the ECHELON-3 Study

2024 ASCO Annual Meeting

Advertisement

Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
ECHELON-3 was a Phase 3 double-blind placebo-controlled trial in patients with diffuse large B-cell lymphoma that had relapsed or refractory disease to prior therapy. In this study, they particularly enrolled those patients that were either ineligible for or had received prior treatment with both CAR-T cell therapy or hematopoietic stem cell transplant. In this trial, investigators evaluated a combination of lenalidomide and rituximab with either brentuximab vedotin or placebo. It was a median of three prior therapies, and in general the patients were heavily pre-treated, including approximately half of patients having primary refractory disease, 30% of patients with prior CAR-T cell exposure, and approximately 15% of patients had prior bispecific antibody exposure. We see with the combination of brentuximab vedotin, lenalidomide and rituximab, that this is a very active regimen, and we're seeing high complete response rates along with encouraging durability at this point. These improved responses were encouragingly seen in both CD30-positive and CD30-negative patients, and this translated into an improvement in progression-free along with overall survival. And importantly, we saw some improvements in really key subsets of patients with high-risk features such as those with high IPI, those patients with prior CAR-T exposure, along with those patients with nongerminal center cell of origin, and this regimen though was not without its own toxicity, and we saw higher incidence of Grade 3 or greater adverse events in the [inaudible 00:01:40] and rituximab arm compared to lenalidomide-rituximab alone, particularly those manifested as hematologic toxicity, along with increased risk of peripheral neuropathy. In general this was an active regimen, and is particularly encouraging for those patients that may not be either eligible for, or have previously received, therapy with things like bispecific antibodies, CAR-T or hematopoietic stem cell transplant. This is currently an interim analysis, and we will need longer follow-up in order to have a better understanding of long-term outcomes, particularly in terms of both safety and efficacy.

Related Videos

Clifford A. Hudis, MD: A Message From ASCO’s CEO

Clifford A. Hudis, MD, of the American Society of Clinical Oncology (ASCO), talks about the 2024 Annual Meeting, and a focus on the compassionate side of cancer care.

Prostate Cancer

Alicia Morgans, MD, MPH, and Samuel R. Denmeade, MD, on Prostate Cancer: Results From the TRANSFORMER Trial

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Samuel R. Denmeade, MD, of Johns Hopkins University School of Medicine, discuss a study showing that patients with metastatic castration-resistant prostate whose disease is progressing on abiraterone with androgen-receptor alterations detected in the blood may benefit from bipolar androgen therapy. Routine liquid biopsy testing may enable further adoption of bipolar treatment (Abstract 5003).

Prostate Cancer

Alicia Morgans, MD, MPH, and Karim Fizazi, MD, PhD, on Prostate Cancer: Study Findings on Health-Related Quality of Life and Pain

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, PhD, of Institut Gustave Roussy and the University of Paris-Saclay, discuss a second interim analysis of the health-related quality of life and pain outcomes in the PSMAfore study (Abstract 5003).

Breast Cancer

Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07

Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer (Abstract 1009).

Prostate Cancer

Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data

Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).

Advertisement

Advertisement




Advertisement